ARTICLE | Clinical News
IDEC-114: Began Phase II trial
January 16, 2001 8:00 AM UTC
Idec Pharmaceuticals Corp. (IDPH), San Diego, Calif. Product: IDEC-114 Business: Autoimmune/Inflammation, Dermatology Therapeutic category: Antibody, Immune modulation Target: Activated T cells expre...